Dr. Reddy’s Laboratories Ltd., through its wholly owned subsidiary Promius Pharma, LLC, announced its fifth consecutive, firstcycleNDA approval for the Proprietary Products Group, a substantial milestone within the pharmaceutical industry.
Impoyz (clobetasol propionate) Cream, 0.025% is a high potency topical steroid approved for the treatment of moderate to severe plaque psoriasis in patients 18 years of age or older. The most common side effect of IMPOYZ Cream includes discoloration of the treated site.
This approval is another example of the deep and broad capabilities within the Proprietary Products business unit at Dr.Reddy’s. The organization has achieved several milestones within drug, device, and formulation research and development for novel therapies.